News

FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Study highlights protein tyrosine phosphatase PTP1B as key driver in heart disease linked to obesity, high-fat diet

A groundbreaking study led by researchers at the Masonic Medical Research Institute (MMRI) has identified a promising ...
STAT21h

For people with diabetes, even a little activity every week is tied to better health

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...
European Medical Journal3h

Dapagliflozin Reverses Cardiac Fibrosis in Diabetic HFpEF, Study Finds

Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...
The Healthy @Reader's Digest3d

Only 50% of Americans Who Need This Heart Attack Prevention Drug Are Taking It, Say Researchers

Tens of thousands of serious health events might be avoided, according to a Johns Hopkins team, if a certain medication was ...
EMBO Press10h

miR-33 inhibition as a novel therapeutic approach for treating muscular dystrophy

MicroRNA-33a and microRNA-33b are encoded within the mammalian SREBF1 and SRBF2 genes, respectively, and both SREBF1 and ...
BioPharma Dive6d

AstraZeneca rare disease drug fails key trial tests

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.